Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Jorge Cortes, Ehab Atallah, David Andorsky, Marlise Luskin, Srinivas Tantravahi, Koji Sasaki, James Dugan, CelesteAnn Bremer, Vivian Oehler, Joshua Zeidner, Moshe Levy, Camille Abboud, Paul Koller, Bonnie Kiner-Strachan, Habte Yimer, Islam Mohamad Sadek, Daisy Yang, Dramane Laine, John (randy) Sabo, Bridget Cooper, Ennan Gu, Michael Mauro
Institutions: Medical College of Wisconsin, Rocky Mountain Cancer Centers, Dana-Farber Cancer Institute, Huntsman Cancer Institute, The University of Texas MD Anderson Cancer Center, Novant Health, Virginia Oncology Associates, Fred Hutch Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Health, Washington University in St. Louis, City Of Hope National Medical Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Texas Oncology, Trinity Mother Frances Hospitals and Clinics, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417020823